Larry Todd Edwards
Larry Todd Edwards's purchase track record
Larry Todd Edwards has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/30/2024 | ARQT | $8K | +3.3% | +8.6% | -1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
Transaction History
| ORKA | ▲ Buy | Grant | 100,000 | $0 | 8/24/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 3,584 | $90K | 3/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 103 | $3K | 3/2/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 30,000 | $0 | 2/27/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 2,052 | $52K | 2/2/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 29,131 | $733K | 11/6/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 4,207 | $84K | 10/2/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 297 | $6K | 10/2/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 7,451 | $105K | 5/19/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 17,000 | $0 | 2/28/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 38,000 | $0 | 2/28/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 2,173 | $28K | 2/3/2025 | View on chart |
| ARQT | ▲ Buy | Open Market | 1,093 | $8K | 11/30/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 3,725 | $37K | 10/2/2024 | View on chart |
| ARQT | ▼ Sell | Open Market | 7,640 | $69K | 5/17/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 60,000 | $0 | 5/16/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 28,000 | $0 | 1/12/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 60,000 | $0 | 9/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.